Keya Medical
AI for Smarter Healthcare
Keya Medical Joins Bayer’s Calantic AI Solution for Radiology
Keya Medical is thrilled to showcase its AI-based augmented CT-FFR analysis through Bayer’s Calantic Digital Solutions platform at ECR2024. Contact us to learn more about our augmentative AI-based CT-FFR analysis.
Keya Medical Presents FDA-cleared CT FFR product at SCCT Global 2024 | Budapest
Visit Keya Medical’s booth at SCCT Global 2024 in Budapest, January 16-19.
Diagnostic Solutions
Treatment Solutions
Solution Suites
Cardiology
Neurology
Pulmonology
Pathology
General Surgery
Cardio Suite
Stroke Suite
Diagnostic Solutions
Treatment Solutions
Solutions Suites
DeepVessel® FFR
Enabling better diagnosis and treatment of patients with coronary artery disease.
DEEPVESSEL FFR is a AI-enabled, non-invasive CT fractional flow reserve (FFRCT) analysis. It is an augmentative physiological functional assessment of the coronary arteries using coronary computer tomography angiograms. The software can reduce unnecessary invasive testing, improve patient safety, and lower the cost of cardiovascular testing.
DEEPVESSEL FFR is FDA Cleared, CE Marked, and NMPA Approved.
FFRCT and DVFFR have transformed my practice, allowing me to provide superior patient care and achieve better outcomes. I am sincerely grateful for this invaluable resource provided by Corazon Imaging.
Scaling your Cardiovascular CT Service and Implementing CT-FFF
Discover the power of automated CT-FFR integration in enhancing your cardiovascular CT services. Learn from Dr. John A Rumberger, Dr. Scott Flamm, and Ralph Gentry how to simplify CT FFR implementation and scale your services.
Keya Medical Presents FDA-cleared CT FFR product at SCCT Global 2024 | Budapest
Visit Keya Medical’s booth at SCCT Global 2024 in Budapest, January 16-19.
Comprehensive R&D Pipeline Solution Suites
Keya Medical is developing a comprehensive R&D pipeline to deliver clinical value throughout the patient care process. The product candidates in our pipeline will be designed for use in early screening, diagnosis, treatment, and post-treatment followup.
Keya Medical: leading AI medical device company
Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers of excellence in Beijing, Shanghai, Shenzhen, and Seattle. To learn more about Keya Medical, follow us on LinkedIn, Twitter, and Facebook.
Latest News
Subscribe to our monthly newsletter to receive exclusive news updates and medical AI insights.
Keya Medical’s CT FFR analysis DEEPVESSEL® is now available in the USA.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
The future of AI-driven, noninvasive CT FFR technology-DeepVessel FFR at 2022 cardiology events in China
Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of DEEPVESSEL FFR.
DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).